Steve E. Krognes, Director at Denali Therapeutics Inc. (DNLI), sold 6,416 shares at $19.43 ($125K) on 2024-01-05, disclosed to the SEC on 2024-01-09.
Seasonal sale ($125k) by Director — this insider has traded DNLI in January in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $19.43 | 3,208 | $62K | 50.0% |
| 2 | $19.43 | 3,208 | $62K | 50.0% |
| Total | $19.43 avg | 6,416 | $125K | 100% |
| Filing → |
| DNLI | SELL | 2025-01-08 | $139K | — | Filing → |
| DNLI | SELL | 2025-01-03 | $608K | — | Filing → |
| DNLI | SELL | 2024-10-02 | $871K | — | Filing → |